Skip to main content

Advertisement

SpringerLink
Log in

Prognostic value of plasmatic tumor M2 pyruvate kinase and carcinoembryonic antigen in the survival of colorectal cancer patients

  • Research Article
  • Published:
Tumor Biology

Abstract

Colorectal cancer (CRC) can be cured in most cases if diagnosed at an early stage. Carcinoembryonic antigen (CEA) remains the most widely used cancer marker for determining prognosis of CRC. Previous studies have shown that plasmatic tumor M2 pyruvate kinase (Tu M2-PK) is highly sensitive in CRC detection at an early stage and equally as good as the results for established tumor markers with clinical potential for cancer prognosis and monitoring. The aim of this study was to assess the prognostic value of Tu M2-PK in plasma using a survival analysis in combination with CEA in serum in patients newly diagnosed with CRC. The initial study included 183 patients who had a complete diagnostic colonoscopy. This cohort study was designed to evaluate the survival in patients with histologically confirmed gastrointestinal cancers (n = 41). Tu M2-PK concentrations in EDTA plasma were determined immunologically using an ELISA assay. Plasma Tu M2-PK levels were significantly higher in patients with distant metastases, stage IV for TNM score, and advanced stage (C+D) subgroups of Dukes than other subgroups. The univariate Cox’s analysis showed that CEA and Tu M2-PK gave high hazard ratios for risk of death (odds ratio CEA = 3.57 and odds ratioTu M2-PK = 2.23) and comparable values in average survival time. The results for both biomarkers did not overlap. These findings suggest that plasmatic Tu M2-PK levels of more than 20 U/mL may be a predictor of death risk.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1
Fig. 2

Similar content being viewed by others

References

  1. Brenner H, Bouvier AM, Foschi R, Hackl M, Larsen IK, Lemmens V, et al. Progress in colorectal cancer survival in Europe, from the late 1980s to the early 21st century: the EUROCARE study. Int J Cancer. 1980;2011. doi:10.1002/ijc.26192.

  2. Thirunavukarasu P, Sukumar S, Sathaiah M, Mahan M, Pragatheeshwar KD, Pingpank JF, et al. C-stage in colon cancer: implications of carcinoembryonic antigen biomarker in staging, prognosis, and management. J Natl Cancer Inst. 2011;103(8):689–97.

    Article  PubMed  Google Scholar 

  3. Goldstein MJ, Mitchell EP. Carcinoembryonic antigen in the staging and follow-up of patients with colorectal cancer. Cancer Invest. 2005;23(4):338–51. Epub 2005/08/17.

    Article  PubMed  Google Scholar 

  4. Duffy MJ, van Dalen A, Haglund C, Hansson L, Holinski-Feder E, Klapdor R, et al. Tumour markers in colorectal cancer: European Group on Tumour Markers (EGTM) guidelines for clinical use. Eur J Cancer. 2007;43(9):1348–60.

    Article  PubMed  CAS  Google Scholar 

  5. Ross JS. Biomarker-based selection of therapy for colorectal cancer. Biomark Med. 2011;5(3):319–32. Epub 2011/06/11.

    Article  PubMed  CAS  Google Scholar 

  6. Kumar Y, Tapuria N, Kirmani N, Davidson BR. Tumor M2-pyruvate kinase: a gastrointestinal cancer marker. Eur J Gastroenterol Hepatol. 2007;19(3):265–76.

    Article  PubMed  CAS  Google Scholar 

  7. Hardt PD, Ewald N. Tumor M2 pyruvate kinase: a tumor marker and its clinical application in gastrointestinal malignancy. Expert Rev Mol Diagn. 2008;8(5):579–85. Epub 2008/09/13.

    Article  PubMed  CAS  Google Scholar 

  8. Zhang B, Chen JY, Chen DD, Wang GB, Shen P. Tumor type M2 pyruvate kinase expression in gastric cancer, colorectal cancer and controls. World J Gastroenterol. 2004;10(11):1643–6. Epub 2004/05/27.

    PubMed  CAS  Google Scholar 

  9. Schulze G. The tumor marker tumor M2-PK: an application in the diagnosis of gastrointestinal cancer. Anticancer Res. 2000;20(6D):4961–4.

    PubMed  CAS  Google Scholar 

  10. Schneider J, Schulze G. Comparison of tumor M2-pyruvate kinase (tumor M2-PK), carcinoembryonic antigen (CEA), carbohydrate antigens CA 19-9 and CA 72-4 in the diagnosis of gastrointestinal cancer. Anticancer Res. 2003;23(6D):5089–93. Epub 2004/02/26.

    PubMed  CAS  Google Scholar 

  11. Schneider J, Bitterlich N, Schulze G. Improved sensitivity in the diagnosis of gastro-intestinal tumors by fuzzy logic-based tumor marker profiles including the tumor M2-PK. Anticancer Res. 2005;25(3V):1507–15.

    PubMed  CAS  Google Scholar 

  12. Goonetilleke KS, Mason JM, Siriwardana P, King NK, France MW, Siriwardena AK. Diagnostic and prognostic value of plasma tumor M2 pyruvate kinase in periampullary cancer: evidence for a novel biological marker of adverse prognosis. Pancreas. 2007;34(3):318–24.

    Article  PubMed  CAS  Google Scholar 

  13. Kumar Y, Pinedo IR, Tapuria N, Zabron A, Davidson BR. A comparison of tumour M2-PK with carcinoembryonic antigen and CA19-9 in patients undergoing liver resection for colorectal metastases. Eur J Gastroenterol Hepatol. 2008;20(10):1006–11.

    Article  PubMed  CAS  Google Scholar 

  14. Fernández-Suárez A, Puente-Gutiérrez JJ, Marín-Moreno MA, Aguilar-Benítez JM, Bernal-Blanco E, Fatela-Cantillo D, Díaz-Iglesias JM. Plasma tumour M2-pyruvate kinase and carcinoembryonic antigen are complementary in early detection of colorectal cancer. Clin Chem. 2010;56(6):A203. Supplements.

    Google Scholar 

  15. Scheer A, Auer RA. Surveillance after curative resection of colorectal cancer. Clin Colon Rectal Surg. 2009;22(4):242–50. Epub 2010/11/03.

    Article  PubMed  Google Scholar 

  16. Locker GY, Hamilton S, Harris J, Jessup JM, Kemeny N, Macdonald JS, et al. ASCO 2006 update of recommendations for the use of tumor markers in gastrointestinal cancer. J Clin Oncol. 2006;24(33):5313–27.

    Article  PubMed  CAS  Google Scholar 

  17. Hardt PD, Mazurek S, Toepler M, Schlierbach P, Bretzel RG, Eigenbrodt E, et al. Faecal tumour M2 pyruvate kinase: a new, sensitive screening tool for colorectal cancer. Br J Cancer. 2004;91(5):980–4.

    PubMed  CAS  Google Scholar 

  18. Katoh H, Yamashita K, Kokuba Y, Satoh T, Ozawa H, Hatate K, et al. Diminishing impact of preoperative carcinoembryonic antigen (CEA) in prognosis of Dukes’ C colorectal cancer. Anticancer Res. 2008;28(3B):1933–41. Epub 2008/07/18.

    PubMed  Google Scholar 

  19. Ugurel S, Bell N, Sucker A, Zimpfer A, Rittgen W, Schadendorf D. Tumor type M2 pyruvate kinase (TuM2-PK) as a novel plasma tumor marker in melanoma. Int J Cancer. 2005;117(5):825–30. Epub 2005/06/16.

    Article  PubMed  CAS  Google Scholar 

  20. Ahmed AS, Dew T, Lawton FG, Papadopoulos AJ, Devaja O, Raju KS, et al. Tumour M2-PK as a predictor of surgical outcome in ovarian cancer, a prospective cohort study. Eur J Gynaecol Oncol. 2007;28(2):103–8. Epub 2007/05/08.

    PubMed  CAS  Google Scholar 

  21. Benesch C, Schneider C, Voelker HU, Kapp M, Caffier H, Krockenberger M, et al. The clinicopathological and prognostic relevance of pyruvate kinase M2 and pAkt expression in breast cancer. Anticancer Res. 2010;30(5):1689–94.

    PubMed  Google Scholar 

  22. Landt S, Jeschke S, Koeninger A, Thomas A, Heusner T, Korlach S, et al. Tumor-specific correlation of tumor M2 pyruvate kinase in pre-invasive, invasive and recurrent cervical cancer. Anticancer Res. 2010;30(2):375–81.

    PubMed  CAS  Google Scholar 

  23. Martinez-Balibrea E, Plasencia C, Gines A, Martinez-Cardus A, Musulen E, Aguilera R, et al. A proteomic approach links decreased pyruvate kinase M2 expression to oxaliplatin resistance in patients with colorectal cancer and in human cell lines. Mol Cancer Ther. 2009;8(4):771–8.

    Article  PubMed  CAS  Google Scholar 

  24. Staib P, Hoffmann M, Schinkothe T. Plasma levels of tumor M2-pyruvate kinase should not be used as a tumor marker for hematological malignancies and solid tumors. Clin Chem Lab Med. 2006;44(1):28–31. Epub 2005/12/27.

    Article  PubMed  CAS  Google Scholar 

  25. Data from the SEER 1973–2005 Public use file diagnosed in years 1998–2000. American Joint Committee on Cancer Staging Manual, 7th ed. New York: Springer; 2010

  26. Hathurusinghe HR, Goonetilleke KS, Siriwardena AK. Current status of tumor M2 pyruvate kinase (tumor M2-PK) as a biomarker of gastrointestinal malignancy. Ann Surg Oncol. 2007;14(10):2714–20.

    Article  PubMed  Google Scholar 

  27. Cerwenka H, Aigner R, Bacher H, Werkgartner G, El-Shabrawi A, Quehenberger F, et al. TUM2-PK (pyruvate kinase type tumor M2), CA19-9 and CEA in patients with benign, malignant and metastasizing pancreatic lesions. Anticancer Res. 1999;19(1B):849–51.

    PubMed  CAS  Google Scholar 

  28. Yamashita K, Watanabe M. Clinical significance of tumor markers and an emerging perspective on colorectal cancer. Cancer Sci. 2009;100(2):195–9.

    Article  PubMed  CAS  Google Scholar 

  29. Stillwell AP, Ho YH, Veitch C. Systematic review of prognostic factors related to overall survival in patients with stage IV colorectal cancer and unresectable metastases. World J Surg. 2011;35(3):684–92. Epub 2010/12/25.

    Article  PubMed  Google Scholar 

  30. Gregoire E, Hoti E, Gorden DL, de la Serna S, Pascal G, Azoulay D. Utility or futility of prognostic scoring systems for colorectal liver metastases in an era of advanced multimodal therapy. Eur J Surg Oncol. 2010;36(6):568–74.

    Article  PubMed  CAS  Google Scholar 

  31. Jessup JM, Gunderson LL, Greene FL, Washington MK, Compton CC, Sobin LH, et al. 2010 staging system for colon and rectal carcinoma. Ann Surg Oncol. 2011;18(6):1513–7. Epub 2011/03/30.

    Article  Google Scholar 

Download references

Conflicts of interest

None

Author information

Authors and Affiliations

  1. Agencia Sanitaria Alto Guadalquivir, Andujar, Jaen, Spain

    Daniel Fatela-Cantillo, Antonio Fernandez-Suarez, Miguel Alonso Marin Moreno, Juan Jesus Puente Gutierrez & Jose Miguel Diaz Iglesias

Authors
  1. Daniel Fatela-Cantillo
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Antonio Fernandez-Suarez
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Miguel Alonso Marin Moreno
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Juan Jesus Puente Gutierrez
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Jose Miguel Diaz Iglesias
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Daniel Fatela-Cantillo.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Fatela-Cantillo, D., Fernandez-Suarez, A., Moreno, M.A.M. et al. Prognostic value of plasmatic tumor M2 pyruvate kinase and carcinoembryonic antigen in the survival of colorectal cancer patients. Tumor Biol. 33, 825–832 (2012). https://doi.org/10.1007/s13277-011-0304-0

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s13277-011-0304-0

Keywords

Search

Navigation